209 related articles for article (PubMed ID: 30670490)
1. Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study.
Wang Z; Kambhampati S; Cheng Y; Ma K; Simsek C; Tieu AH; Abraham JM; Liu X; Prasath V; Duncan M; Stark A; Trick A; Tsai HL; Wang H; He Y; Khashab MA; Ngamruengphong S; Shin EJ; Wang TH; Meltzer SJ
Clin Cancer Res; 2019 Apr; 25(7):2127-2135. PubMed ID: 30670490
[TBL] [Abstract][Full Text] [Related]
2. Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens.
Chettouh H; Mowforth O; Galeano-Dalmau N; Bezawada N; Ross-Innes C; MacRae S; Debiram-Beecham I; O'Donovan M; Fitzgerald RC
Gut; 2018 Nov; 67(11):1942-1949. PubMed ID: 29084829
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus.
Alvi MA; Liu X; O'Donovan M; Newton R; Wernisch L; Shannon NB; Shariff K; di Pietro M; Bergman JJ; Ragunath K; Fitzgerald RC
Clin Cancer Res; 2013 Feb; 19(4):878-88. PubMed ID: 23243219
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
5. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
[TBL] [Abstract][Full Text] [Related]
6. Automated cytological detection of Barrett's neoplasia with infrared spectroscopy.
Old O; Lloyd G; Isabelle M; Almond LM; Kendall C; Baxter K; Shepherd N; Shore A; Stone N; Barr H
J Gastroenterol; 2018 Feb; 53(2):227-235. PubMed ID: 28501919
[TBL] [Abstract][Full Text] [Related]
7. Development of a risk prediction model for Barrett's esophagus in an Australian population.
Ireland CJ; Fielder AL; Thompson SK; Laws TA; Watson DI; Esterman A
Dis Esophagus; 2017 Nov; 30(11):1-8. PubMed ID: 28881896
[TBL] [Abstract][Full Text] [Related]
8. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus.
Moinova HR; LaFramboise T; Lutterbaugh JD; Chandar AK; Dumot J; Faulx A; Brock W; De la Cruz Cabrera O; Guda K; Barnholtz-Sloan JS; Iyer PG; Canto MI; Wang JS; Shaheen NJ; Thota PN; Willis JE; Chak A; Markowitz SD
Sci Transl Med; 2018 Jan; 10(424):. PubMed ID: 29343623
[TBL] [Abstract][Full Text] [Related]
9. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.
Sato F; Jin Z; Schulmann K; Wang J; Greenwald BD; Ito T; Kan T; Hamilton JP; Yang J; Paun B; David S; Olaru A; Cheng Y; Mori Y; Abraham JM; Yfantis HG; Wu TT; Fredericksen MB; Wang KK; Canto M; Romero Y; Feng Z; Meltzer SJ
PLoS One; 2008 Apr; 3(4):e1890. PubMed ID: 18382671
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
[TBL] [Abstract][Full Text] [Related]
11. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett's esophagus in patients with chronic gastroesophageal reflux.
Lin OS; Schembre DB; Mergener K; Spaulding W; Lomah N; Ayub K; Brandabur JJ; Bredfeldt J; Drennan F; Gluck M; Jiranek GC; McCormick SE; Patterson D; Kozarek RA
Gastrointest Endosc; 2007 Apr; 65(4):577-83. PubMed ID: 17324414
[TBL] [Abstract][Full Text] [Related]
12. A genomic biomarker-based model for cancer risk stratification of non-dysplastic Barrett's esophagus patients after extended follow up; results from Dutch surveillance cohorts.
Hoefnagel SJM; Mostafavi N; Timmer MR; Lau CT; Meijer SL; Wang KK; Krishnadath KK
PLoS One; 2020; 15(4):e0231419. PubMed ID: 32282835
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
14. Screening for Barrett's esophagus.
Zakko L; Lutzke L; Wang KK
Minerva Med; 2017 Feb; 108(1):28-42. PubMed ID: 27792223
[TBL] [Abstract][Full Text] [Related]
15. [The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus].
Osminin SV; Vetshev FP; Rudenko VV; Zaletaev DV; Khorobrykh TV; Nemtsova MV
Klin Lab Diagn; 2016 Oct; 61(10):681-5. PubMed ID: 30615323
[TBL] [Abstract][Full Text] [Related]
16. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer.
Jin Z; Olaru A; Yang J; Sato F; Cheng Y; Kan T; Mori Y; Mantzur C; Paun B; Hamilton JP; Ito T; Wang S; David S; Agarwal R; Beer DG; Abraham JM; Meltzer SJ
Clin Cancer Res; 2007 Nov; 13(21):6293-300. PubMed ID: 17975140
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
[TBL] [Abstract][Full Text] [Related]
19. Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study.
Timmer MR; Martinez P; Lau CT; Westra WM; Calpe S; Rygiel AM; Rosmolen WD; Meijer SL; Ten Kate FJ; Dijkgraaf MG; Mallant-Hent RC; Naber AH; van Oijen AH; Baak LC; Scholten P; Böhmer CJ; Fockens P; Maley CC; Graham TA; Bergman JJ; Krishnadath KK
Gut; 2016 Oct; 65(10):1602-10. PubMed ID: 26104750
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic TriModal imaging and biomarkers for neoplasia conjoined: a feasibility study in Barrett's esophagus.
Boerwinkel DF; Di Pietro M; Liu X; Shariff MK; Lao-Sirieix P; Walker CE; Visser M; O' Donovan M; Kaye P; Bergman JJ; Fitzgerald RC
Dis Esophagus; 2014 Jul; 27(5):435-43. PubMed ID: 23067399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
